The IHC - CD43 test, or immunohistochemistry for CD43, is a diagnostic procedure used by medical professionals to help identify certain diseases, particularly those related to the immune system. CD43, also known as leukosialin or sialophorin, is a protein expressed on the surface of many cells in the immune system, including T cells, B cells, monocytes, and granulocytes. Its presence or absence, along with its pattern of expression, can provide valuable clues in diagnosing a variety of health conditions, most notably hematological malignancies (blood cancers) such as lymphomas and leukemias.
Immunohistochemistry (IHC) is a laboratory technique that uses antibodies to detect specific proteins, such as CD43, in tissue samples. It is a powerful tool in pathological examinations, allowing the visualization of cellular components within a tissue structure, providing both molecular and morphological information. The analysis and interpretation of IHC involve the use of a microscope to examine the stained tissue sample.
Test NameIHC - CD43
Sample TypeTissue Sample
Preparations RequiredThere are no specific instructions for preparation before undergoing the IHC - CD43 test
Report Time3 days
What is the purpose of the IHC - CD43 test?
The IHC - CD43 test is primarily used to help diagnose certain types of lymphomas and leukemias. It helps in differentiating these from other diseases that can appear similar under the microscope.
How is the test performed?
The test is performed on a tissue sample, usually taken through a biopsy. This sample is then treated with antibodies that bind to the CD43 protein. If CD43 is present, the antibodies will stick to it and can be visualized under a microscope using special stains.
Home Sample Collection Process
1
Book your convenient slot
2
Sample Collection by Phlebotomist
3
Reporting of the sample at lab
4
Download Reports
Frequently Asked Questions
There are no specific preparations needed for this test. You may be asked to fast or refrain from taking certain medications before the biopsy procedure, depending on your doctor's instructions.
The IHC - CD43 test itself isn't painful, but the biopsy procedure to obtain the tissue sample may cause some discomfort or pain. Your healthcare provider will use local or general anesthesia to minimize discomfort during the procedure.
If CD43 is detected in your tissue sample, it may suggest the presence of a lymphoma or leukemia. However, the test is typically used in conjunction with other diagnostic tests for a definitive diagnosis. Your doctor will interpret your results in the context of your overall clinical picture.
The IHC - CD43 test is typically not used for disease monitoring, it is primarily a diagnostic tool. Other tests may be used to monitor the progression or response to treatment of lymphomas or leukemias.
The risks associated with the IHC - CD43 test are primarily related to the biopsy procedure. These might include infection, bleeding, or reactions to anesthesia. The laboratory procedure itself poses minimal risk.
Technical issues such as improper sample handling or issues with the staining process can affect the test results. Your doctor will interpret your results, considering these potential factors.
There are other tests and procedures that may be used to diagnose lymphomas and leukemias, such as flow cytometry, molecular genetic tests, or cytogenetic analysis. The choice of test depends on various factors and your doctor's clinical judgment.
If your test results are abnormal, it could indicate a possible disease or condition, such as a lymphoma or leukemia. Your doctor will discuss these results with you and recommend a treatment plan, if necessary.
If you are pregnant and need this test, your doctor will consider the potential risks and benefits. If the test is essential for diagnosing a serious condition, it might be performed even during pregnancy.
The presence of other illnesses or conditions could potentially affect your test results. However, the IHC - CD43 test is usually very specific, and these factors are unlikely to cause significant changes in the results.
The turnaround time for the test results usually ranges from 7 to 10 days. However, this can vary depending on the lab and the complexity of the analysis.
No, the IHC - CD43 test requires a tissue sample that needs to be obtained through a biopsy. This procedure must be performed by a healthcare provider in a medical setting. The sample is then sent to a specialized lab for analysis.
If your IHC - CD43 test results suggest a problem, you should consult with a hematologist or oncologist who specializes in blood diseases and cancers. They will guide you on the next steps and appropriate treatment, if necessary. Understanding the results of the IHC - CD43 test can play a key role in the diagnosis and management of various diseases, particularly lymphomas and leukemias. By allowing for the visualization of specific proteins like CD43, it offers unique insights that contribute to a comprehensive clinical picture. Always discuss your results and any concerns you have with your healthcare provider. They are best positioned to interpret your results and guide your care.
The IHC - CD43 test is not typically done at regular intervals. It is usually performed when a doctor suspects a patient may have a disease that this test can help diagnose, such as certain types of lymphomas or leukemias.
No, there are no specific age restrictions for undergoing the IHC - CD43 test. The decision to order this test is based on the clinical judgment of the healthcare provider, considering the patient's symptoms and medical history.
As the IHC - CD43 test detects the presence of specific proteins in tissue samples, medications are unlikely to impact the results. However, you should always inform your healthcare provider about any medications or supplements you're taking, as they can impact the overall assessment of your health.
While the IHC - CD43 test can aid in the diagnosis of certain types of lymphomas and leukemias, it may not detect all forms. Other diagnostic tests are typically used in conjunction with the IHC - CD43 test for a comprehensive evaluation.
The IHC - CD43 test can provide some information about the nature of your disease. However, predicting the aggressiveness of a cancer often involves many factors and tests. Your healthcare provider will interpret the results in the context of your overall health and other diagnostic test results.
It depends on the type of anesthesia that will be used during the biopsy. If general anesthesia is required, you may be asked to fast before the procedure. It's essential to follow your healthcare provider's instructions to ensure a safe and effective procedure.
If you experience significant bleeding, signs of infection (like increasing pain, redness, swelling, or pus), or any other concerning symptoms after the biopsy, it's crucial to contact your healthcare
